ClinicalTrials.gg
Not yet recruitingNCT07844096PEN-CoolUpdated Sep 28, 2026

COOLing of the Ischemic PENumbra in Patients With Acute Ischemic Stroke.

An interventional study of PEN-Cool Conductive Head-and-Neck Cooling System and Standard Reperfusion Therapy / Routine Care in Acute Ischemic Stroke, sponsored by Christian Medical College and Hospital, Ludhiana, India. Not yet recruiting at 5 sites in India. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Christian Medical College and Hospital, Ludhiana, India · Not applicable, Interventional, and Treatment

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Ischemic Stroke with a site in India — 5 open to participants now, 6 under way, 3 of them phase 3. Ischemic Stroke · India.

Planned enrollment
14th of 15
55 · median 232
Started
2027
with 1 other
No phase
6 of 17
2 open now
Registered
15th of 17
by date
Lead sponsor
2 of 17
Christian Medical College and Hospital, Ludhiana, India

Among the 17 studies in Ischemic Stroke with a site in India, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2027, is one of 6 with no phase, and was the 15th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

5 of the 17 studies in Ischemic Stroke with a site in India are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ischemic Stroke with a site in India, or all of them as a file.
02

Study summary

This study will develop and validate a novel, active/conductive combined head and neck cooling system to selectively cool the ischemic penumbra during the acute phase of stroke, reducing neuronal damage and improving stroke outcomes. It complements existing reperfusion therapies offering a scalable neuroprotective option which will have wider implications across diverse healthcare settings.

PHASE I: Technology Development \& Test Bench Optimization (Years 1-2) PHASE II: Validation in healthy volunteers (Year 3)

PHASE III: Pilot, multicenter, randomized controlled (Phase 2a) trial (Year 4-5):

Read the detailed description

PEN-Cool is a pilot, multicentre, randomized controlled trial evaluating a novel non-invasive active conductive combined head-and-neck cooling system for selective brain cooling in adults with acute ischemic stroke receiving reperfusion therapy. The study is part of a phased translational research programme involving technology development, validation in healthy volunteers, and clinical evaluation in patients with acute ischemic stroke.

The clinical trial will enroll 40 adult patients with acute ischemic stroke who are eligible for intravenous thrombolysis, endovascular thrombectomy, or both. Participants will be centrally randomized in a 1:1 ratio to either adjunctive selective brain cooling plus standard reperfusion therapy or standard reperfusion therapy alone.

In the intervention group, the conductive cooling system will be applied to the scalp and anterolateral and posterolateral neck. Cooling will begin before intravenous thrombolysis and/or endovascular thrombectomy in the emergency department or angiography suite and will continue for up to 120 minutes. The cooling interface will deliver temperatures ranging from -5°C to 0°C. Brain temperature will be monitored non-invasively using infrared tympanic membrane thermometry, while core body temperature will be monitored using a rectal or esophageal probe. Blood pressure, heart rate, and oxygen saturation will also be monitored.

Cooling will be discontinued if predefined safety or tolerability criteria are met, including intolerance, persistent cold-related shivering despite passive warming, core body temperature of 35°C or below, uncontrolled hypertension, symptomatic bradycardia or other unexpected medical events, or procedural complications.

The primary feasibility outcome is adherence to the cooling intervention, defined as receiving head cooling for at least 60% of the intended total cooling duration. Secondary feasibility outcomes include interruptions in cooling and monthly enrollment rate. Efficacy outcomes include early neurological improvement, defined as a 30% or greater improvement in NIHSS score at 24 hours, and good functional outcome, defined as a modified Rankin Scale score of 0-2 at 3 months. Safety outcomes include symptomatic bradyarrhythmia, uncontrolled hypertension, cold-related shivering, cervical or cerebral vasospasm requiring intra-arterial vasodilators, symptomatic intracranial hemorrhage, pneumonia, and mortality through 3 months. Process outcomes include time from hospital arrival to initiation of cooling and time from arrival to reperfusion therapy.

The study will assess whether selective brain cooling can be safely and feasibly integrated into acute ischemic stroke care without delaying established reperfusion workflows and will generate preliminary safety, feasibility, and efficacy data to inform a future adequately powered multicentre randomized controlled trial.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • Selective brain cooling
  • Conductive cooling
  • PEN-Cool
  • Therapeutic hypothermia
  • Neuroprotection
  • Ischemic penumbra
  • Reperfusion therapy
  • Intravenous thrombolysis
  • Endovascular thrombectomy
  • Head and neck cooling
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PHASE l

  1. Healthy adult participants of any gender aged 18 years or older and able to provide
  2. .

PHASE II

1. Adult patients of any gender, presenting with acute ischemic stroke and eligible for reperfusion therapy IVT or EVT or Both as per guidelines.

Exclusion criteria

Exclusion Criteria:

PHASE I

  1. History of uncontrolled hypertension or cardiovascular disease.
  2. Hematologic dyscrasias that can affect thrombosis like cryoglobulinemia or sickle cell disease or serum cold agglutinins.
  3. Vasospastic disorders like Raynaud or thromboangiitis obliteran.
  4. Skin lesions not allowing secure application of the cooling system

PHASE II

  1. Surface Body temperature less than and equal to 35 degree Celcius at baseline
  2. Blood pressure more than or equal to 185 by 110 mmHg not responsive to guideline-directed intravenous antihypertensive therapy
  3. Known to hypothermia including hemodynamically unstable patients with new or symptomatic bradyarrhythmia known hematologic dyscrasias that affect thrombosis or vasospastic disorders such as Raynaud syndrome or thrombo angiitis obliterans.
  4. Skin lesions on scalp or neck preventing secure application of the cooling cap.
  5. Pre-morbid mRS more than or equal to 3
  6. Patients with known diseases or conditions resulting in an expected of less than or equal to 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Selective Brain Cooling + Standard Reperfusion Therapy

    Participants will receive adjunctive non-invasive selective brain cooling using the novel active conductive combined head-and-neck cooling system in addition to standard reperfusion therapy (intravenous thrombolysis, endovascular thrombectomy, or both).

    Device: PEN-Cool Conductive Head-and-Neck Cooling System

  • Active comparator
    Standard Reperfusion Therapy / Routine Care

    Participants will receive standard of care management for acute ischemic stroke according to institutional practice, including indicated intravenous thrombolysis and/or endovascular thrombectomy, without selective brain cooling.

    Other: Standard Reperfusion Therapy / Routine Care

Interventions

  • DevicePEN-Cool Conductive Head-and-Neck Cooling System

    A novel non-invasive active conductive combined head-and-neck cooling system designed to induce selective brain cooling while avoiding systemic hypothermia.Cooling will begin before IVT and/or EVT in the emergency department or angiography suite and continue for up to 120 minutes. The cooling system will contact the scalp and anterolateral and posterolateral neck and deliver temperatures ranging from -5°C to 0°C. Brain and core temperatures and physiological parameters will be monitored throughout the cooling period along with standard reperfusion.

  • OtherStandard Reperfusion Therapy / Routine Care

    Standard of care management for acute ischemic stroke according to institutional practice, including intravenous thrombolysis, endovascular thrombectomy, or both when indicated.

06

What researchers measure

Primary outcomes

  1. Adherence to the intervention cooling system.

    Phase III (Feasibility outcomes) Primary feasibility outcome defined as the proportion of participants who will be adherent to the intervention. Adherence defined as undergoing head cooling for more than equal to 60 percent of the total time from the first application of the head and neck cooling system.

    Time frame: 3 months

Secondary outcomes

  1. Interruption of cooling system

    PHASE III Secondary feasibility outcomes include interruption of cooling and the monthly enrollment rate. High recrutements are good outcome.

    Time frame: 3 months

  2. NIHSS

    Phase III Efficacy outcomes: Early neurological improvement, defined as a 30% or greater improvement in the NIHSS score at 24 h. Lower NIHSS is good outcome

    Time frame: 24 hours

  3. mRS

    Phase III Good functional outcome at 3 months Good functional outcome, defined as an mRS of 0, 1, or 2, at 3 months assessed by telephone interview conducted by a trained researcher. Lower mRS indicates good outcome.

    Time frame: 3 months

  4. Safety outcome

    Phase III Including bradyarrhythmia, pneumonia, shivering and cerebral vasospasm at 3 months.

    Time frame: 3 months

07

Study locations

5 sites
08

References and documents

Publications

  • Goyal M, Ospel JM, Ganesh A, Dowlatshahi D, Volders D, Mohlenbruch MA, Jumaa MA, Nimjee SM, Booth TC, Buck BH, Kennedy J, Shankar JJ, Dorn F, Zhang L, Hametner C, Nardai S, Zafar A, Diprose W, Vatanpour S, Stebner A, Bosshart S, Singh N, Sebastian I, Uchida K, Ryckborst KJ, Fahed R, Hu SX, Vollherbst DF, Zaidi SF, Lee VH, Lynch J, Rempel JL, Teal R, Trivedi A, Bode FJ, Ogungbemi A, Pham M, Orosz P, Abdalkader M, Taschner C, Tarpley J, Poli S, Singh RJ, De Leacy R, Lopez G, Sahlas D, Chen M, Burns P, Schaafsma JD, Marigold R, Reich A, Amole A, Field TS, Swartz RH, Settecase F, Lenzser G, Ortega-Gutierrez S, Asdaghi N, Lobotesis K, Siddiqui AH, Berrouschot J, Mokin M, Ebersole K, Schneider H, Yoo AJ, Mandzia J, Klostranec J, Jadun C, Patankar T, Sauvageau E, Lenthall R, Peeling L, Huynh T, Budzik R, Lee SK, Makalanda L, Levitt MR, Perry RJ, Hlaing T, Jahromi BS, Singh P, Demchuk AM, Hill MD; ESCAPE-MeVO Investigators. Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. N Engl J Med. 2025 Apr 10;392(14):1385-1395. doi: 10.1056/NEJMoa2411668. Epub 2025 Feb 5. PubMed 39908448 ↗
  • Pandian JD, Sylaja PN, Lackland DT, Babu V, Kumar Paramasivan N, Sebastian I, Parati G, Anderson CS, Ovbiagele B, Fisher M, Martins S, Whelton P. World Stroke Organization and World Hypertension League position statement on hypertension control strategies in prevention and management of stroke. Int J Stroke. 2025 Feb;20(2):151-165. doi: 10.1177/17474930241309276. Epub 2025 Jan 3. PubMed 39670456 ↗
  • Pandian JD, Kalkonde Y, Sebastian IA, Felix C, Urimubenshi G, Bosch J. Stroke systems of care in low-income and middle-income countries: challenges and opportunities. Lancet. 2020 Oct 31;396(10260):1443-1451. doi: 10.1016/S0140-6736(20)31374-X. PubMed 33129395 ↗
  • Sebastian IA, Gandhi DBC, Sylaja PN, Paudel R, Kalkonde YV, Yangchen Y, Gunasekara H, Injety RJ, Vijayanand PJ, Chawla NS, Oo S, Hla KM, Tenzin T, Pandian JD. Stroke systems of care in South-East Asia Region (SEAR): commonalities and diversities. Lancet Reg Health Southeast Asia. 2023 Oct 9;17:100289. doi: 10.1016/j.lansea.2023.100289. eCollection 2023 Oct. PubMed 37849930 ↗
  • Kalra LP, Khatter H, Ramanathan S, Sapehia S, Devi K, Kaliyaperumal A, Bal D, Sebastian I, Kakarla R, Singhania A, Rathore S, Klinsing S, Pandian JD, Foerch C. Serum GFAP for stroke diagnosis in regions with limited access to brain imaging (BE FAST India). Eur Stroke J. 2021 Jun;6(2):176-184. doi: 10.1177/23969873211010069. Epub 2021 May 11. PubMed 34414293 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with external researchers.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2027; primary completion for Aug 2031, 47 months later.

Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 47 months is above that.

Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Sep 28, 2026
StartEst.
Sep 1, 2027
Primary completionEst.
Aug 30, 2031
CompletionEst.
Aug 30, 2031
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844096
Lead sponsor
Christian Medical College and Hospital, Ludhiana, India
Collaborators
Indian Council of Medical Research
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Sep 1, 2027 (estimated)
Primary completion
Aug 30, 2031 (estimated)
Completion
Aug 30, 2031 (estimated)
Last update
Sep 28, 2026

Study contacts

Dr Ivy A Sebastian
Contact
ivy29cmc@gmail.com
9999464986
Dr Jeyaraj D Pandian, MD DM
Contact
ivy29cmc@gmail.com
9915784750
Dr Jeyaraj D Pandian
principal investigator · Christian Medical College and Hospital, Ludhiana, India
Dr ATUL PHILLIPS
principal investigator · Christian Medical College and Hospital, Ludhiana, India
Dr Ivy A Sebastian
principal investigator · Christian Medical College and Hospital, Ludhiana, India

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion